Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial

Journal of Clinical Psychopharmacology
Baruch SpivakAbraham Weizman

Abstract

Motor vehicle accidents (MVAs) are a leading cause of posttraumatic stress disorder (PTSD) in the general population. Alterations in norepinephrine and serotonin systems have been proposed as mechanisms involved in the pathophysiology of the condition, with treatment directed at these neurotransmitter systems. Reboxetine, a selective norepinephrine reuptake inhibitor, exhibits high affinity and selectivity for the human norepinephrine transporter. Inasmuch as PTSD may be associated with dysregulation of noradrenergic activity, the present double-blind randomized clinical trial intended to evaluate reboxetine's efficacy in the management of MVA-related PTSD and to compare its efficacy with a medication commonly used in PTSD, the selective serotonin reuptake inhibitor fluvoxamine. Forty patients with MVA-related PTSD attending a local community mental health outpatient clinic were randomized to receive a fixed dose of either reboxetine (8 mg/d) or fluvoxamine (150 mg/d) in a double-blind fashion for a period of 8 weeks. At baseline and at study end point, the 2 subgroups demonstrated no statistical differences in scores on PTSD, depression, and anxiety rating scales. Both medications led to significant improvements in all clinica...Continue Reading

References

May 1, 1992·The Journal of Nervous and Mental Disease·R YehudaJ W Mason
Jun 1, 1991·The Journal of Nervous and Mental Disease·T R KostenE L Giller
Mar 1, 1990·Archives of General Psychiatry·J DavidsonJ O Cavenar
Jun 1, 1981·International Journal of Epidemiology·E D Richter
Sep 11, 1993·BMJ : British Medical Journal·R MayouR Duthie
Oct 18, 1993·The Medical Journal of Australia·M M GreenW M Griggs
Apr 1, 1993·Archives of General Psychiatry·S M SouthwickD S Charney
Sep 1, 1996·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·K KuchR J Evans
Jan 4, 1998·Psychosomatic Medicine·R MayouB Bryant
Feb 24, 1998·Journal of Clinical Psychopharmacology·J R DavidsonL A Tupler
Jun 2, 1998·Comprehensive Psychiatry·A BlaszczynskiP Panasetis
Jun 5, 1999·Depression and Anxiety·K M Connor, J R Davidson
Jan 6, 2000·The British Journal of Psychiatry : the Journal of Mental Science·K M ConnorJ R Davidson
Jun 5, 2001·Depression and Anxiety·F W WeathersJ R Davidson
Aug 2, 2001·The American Journal of Psychiatry·T D GeraciotiJ W Kasckow
Jan 30, 2002·Depression and Anxiety·Rodrigo EscalonaJonathan R T Davidson
Oct 22, 2002·Expert Opinion on Pharmacotherapy·Ann C Schwartz, Barbara O Rothbaum
Jan 29, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Meera VaswaniSubramanyam Ramesh
Jan 1, 1959·The British Journal of Medical Psychology·M HAMILTON
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON

❮ Previous
Next ❯

Citations

Nov 18, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Ismene L PetrakisJohn H Krystal
Feb 4, 2015·The British Journal of Psychiatry : the Journal of Mental Science·Mathew HoskinsJonathan I Bisson
Apr 1, 2009·Brain Research·Lakshmi N Ravindran, Murray B Stein
Jan 1, 2009·Expert Review of Clinical Pharmacology·Christopher P AldermanAnita C Marwood
Jun 10, 2010·Journal of Psychopharmacology·N J KalkA R Lingford-Hughes
Dec 27, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Yassine BentefourRené Garcia
Feb 11, 2010·The Journal of Nervous and Mental Disease·Ido Lurie, Stephen Z Levine
Oct 25, 2008·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Borwin BandelowJohann Vega
Jun 12, 2020·Personality Neuroscience·N McNaughton, P Glue

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.